Infantile Arteriosclerosis

Infantile arteriosclerosis is an old name for a rare, often life-threatening condition in which a baby develops hard calcium deposits inside the walls of medium- and large-sized arteries, together with thickening of the inner lining (intima). This hardening and narrowing can begin before birth and can severely limit blood flow to vital organs like the heart, lungs, brain, kidneys, and intestines. Today the condition is best known as Generalized Arterial Calcification of Infancy (GACI), usually caused by changes (pathogenic variants) in the ENPP1 gene and, less often, the ABCC6 gene. These gene problems reduce the body’s natural “anti-calcification” signal (pyrophosphate), so calcium crystals build up in arteries much too early. Babies may show breathing trouble, high blood pressure, heart failure, poor feeding, and weak pulses in the first days or weeks of life. Without early recognition and careful treatment, it can be fatal in infancy; however, some children do survive and later develop issues like low phosphate rickets and hearing loss. Orpha+3NCBI+3National Organization for Rare Disorders+3

---

Other names

GACI (Generalized Arterial Calcification of Infancy). This is the modern, preferred name used in medical references and genetics resources. It emphasizes that the calcification is widespread and starts in infancy. NCBI+1

Idiopathic infantile arterial calcification (IIAC). This is the older term you will see in many case reports. “Idiopathic” was used before the main genetic causes were discovered. PMC+1

ENPP1-related GACI (also called GACI type 1). When GACI is caused by harmful variants in the ENPP1 gene, many sources call it type 1. ENPP1 loss lowers pyrophosphate (PPi), the natural brake on soft-tissue mineralization. NCBI+1

ABCC6-related GACI (also called GACI type 2). A smaller group has variants in ABCC6, a gene linked to ectopic calcification pathways; some families show overlap with pseudoxanthoma elasticum biology. BioMed Central+1

Arterial calcification of infancy / arterial calcification, generalized, of infancy (MONDO/Orphanet naming). Rare-disease catalogs and registries list the disorder under these names. GARD Information Center+1

---

Types

1. Type by gene (GACI type 1 vs type 2). Doctors most often divide GACI by the gene involved—ENPP1 (type 1) or ABCC6 (type 2)—because this helps with genetic counseling and increasingly with research-based treatments targeting the pathway. ScienceDirect
2. Type by timing (prenatal vs postnatal onset). Some fetuses show problems on ultrasound before birth (like bright, echo-dense vessel walls or heart issues). Others present after birth with heart failure or severe hypertension. The timing affects how care teams plan delivery and immediate neonatal management. BioMed Central+1
3. Type by dominant features (calcification-predominant vs stenosis-predominant). Some infants mainly have extensive calcium deposition; others show more narrowing and thickening of the inner artery layer. Either pattern can be severe and may evolve over time. PubMed

---

Causes and contributors

1. ENPP1 gene variants. Harmful changes in ENPP1 lower extracellular pyrophosphate (PPi), the body’s key natural inhibitor of soft-tissue calcification, letting calcium crystals form in arteries too early. NCBI+1

2. ABCC6 gene variants. Pathogenic ABCC6 changes impair a pathway that normally supplies PPi precursors, also promoting ectopic calcification in arteries of infants. ScienceDirect+1

3. Autosomal recessive inheritance. Most affected babies inherited one faulty copy of the gene from each parent; parents are typically healthy carriers. NCBI

4. Low extracellular pyrophosphate (PPi). PPi normally prevents hydroxyapatite crystals from forming in soft tissues; when PPi is low, arterial walls calcify and stiffen. PMC

5. Intimal proliferation after calcification. The artery’s inner lining thickens on top of the mineral deposits, further narrowing the lumen and restricting blood flow. MedlinePlus

6. Prenatal onset. Disease activity often starts in utero, so babies can be symptomatic at or soon after birth. Early onset means organs face reduced blood flow during a critical growth window. PubMed

7. Systemic hypertension as a driver. High blood pressure develops because of narrowed arteries and also worsens arterial injury, creating a harmful cycle. GARD Information Center

8. Ischemia of vital organs. Coronary, renal, cerebral, and mesenteric arteries can be affected, so heart, kidney, brain, and gut injury further amplify the disease impact. PubMed

9. Genetic heterogeneity (different variant types). Nonsense, missense, and splice variants can all cause disease; different variants may be linked to different severities. Frontiers

10. Consanguinity (when present). In some reports, parental relatedness increases the chance both carry the same rare variant, raising risk for autosomal recessive disorders. PubMed

11. Shared pathway biology with PXE (in ABCC6 cases). The ABCC6 pathway connects to disorders of elastic tissue mineralization, explaining why calcification targets elastic-rich arterial layers. ScienceDirect

12. Cascade effects on heart muscle. Calcified coronary arteries may cause myocardial ischemia or infarction in infants, which quickly worsens overall circulation. PubMed

13. Secondary endocrine/mineral complications in survivors. Children who live past infancy can develop hypophosphatemic rickets, which reflects long-term mineralization pathway disturbance. NCBI

14. Hearing involvement in survivors. Sensorineural hearing loss appears in some long-term survivors, reflecting broader ectopic mineralization effects beyond arteries. NYMAC

15. Renal calcifications (nephrocalcinosis). Calcification can extend to kidneys; impaired renal function can then aggravate blood pressure and mineral balance. NYMAC

16. Vascular remodeling after injury. Ongoing vessel stress from stiffness and high pressure can remodel artery walls over time, maintaining stenosis even if calcification slows. PubMed

17. Placental vascular changes (in severe fetal disease). Because disease can start in utero, placental perfusion may be affected, contributing to fetal distress or growth problems. BioMed Central

18. Potential gene–environment interactions (research stage). Most cases are genetic; modifiers of mineral metabolism are being studied but are not yet established causes in routine care. PMC

19. Limited PPi-producing reserve in the liver (ABCC6 biology). ABCC6 is highly expressed in the liver; reduced ATP/PPi export from hepatocytes may lower systemic anti-calcification capacity. ScienceDirect

20. Natural history pressures in early months. The combination of fixed arterial narrowings and rapidly rising newborn metabolic demands explains why the first year carries the highest risk. gimjournal.org

---

Common symptoms and signs

1. Breathing trouble (respiratory distress). Stiff, narrowed lung or heart arteries and heart strain can make a baby breathe fast and hard soon after birth. GARD Information Center

2. Poor feeding and tiring easily. Low blood flow and heart failure make feeding exhausting, so weight gain is slow. National Organization for Rare Disorders

3. Sweating with feeds. Babies in heart failure often sweat and tire with bottle or breast feeds. National Organization for Rare Disorders

4. Bluish lips or skin (cyanosis). If oxygen delivery drops, the skin and lips can look blue. GARD Information Center

5. Pale or cool skin with weak pulses. Narrowed arteries reduce pulses in arms/legs; hands and feet may feel cool. National Organization for Rare Disorders

6. Fast heartbeat or irregular rhythm. The heart works harder against stiff arteries and may beat fast or abnormally. GARD Information Center

7. Enlarged heart (cardiomegaly). The heart muscle thickens or dilates from constant pressure and poor blood supply. PubMed

8. Heart murmur or vascular “bruit.” Turbulent flow across narrowed segments can create extra sounds doctors hear with a stethoscope. National Organization for Rare Disorders

9. Swelling (edema). Heart failure can cause leg, body, or facial swelling in infants. National Organization for Rare Disorders

10. High blood pressure (systemic hypertension). Narrowed systemic arteries push pressures up, even in newborns. GARD Information Center

11. Irritability or lethargy. Poor perfusion or high blood pressure can make babies unusually fussy or sleepy. National Organization for Rare Disorders

12. Seizures or stroke-like episodes. Calcified/narrow brain arteries can cut blood flow and cause neurologic symptoms. PubMed

13. Poor growth (failure to thrive). Feeding difficulty plus chronic illness slow height and weight gain. National Organization for Rare Disorders

14. Signs of poor kidney perfusion. Reduced urine, rising creatinine, or electrolyte issues can appear if renal arteries are involved. PubMed

15. Eye findings in some children. Survivors may later develop eye complications like choroidal neovascularization; these are managed by eye specialists. NCBI

---

Diagnostic tests

A) Physical examination

1. Four-limb blood pressure. Measuring BP in both arms and legs can reveal high pressures or arm–leg differences that suggest arterial narrowings. GARD Information Center

2. Pulse checks in all limbs. Weak or absent pulses (especially femoral) can signal narrowed aorta or major branches. National Organization for Rare Disorders

3. Cardiac and vascular auscultation. Murmurs or “bruits” point toward turbulent flow across tight segments. National Organization for Rare Disorders

4. Signs of heart failure. Rapid breathing, liver edge enlargement, swelling, and poor feeding are bedside clues to reduced cardiac output. GARD Information Center

5. Growth and hydration status. Plotting weight/length/head size and checking hydration help quantify severity and guide support. National Organization for Rare Disorders

B) Manual/bedside tests

6. Pulse oximetry. A simple finger/foot sensor shows oxygen saturation; low or fluctuating values can reflect limited blood flow or lung-heart strain. GARD Information Center

7. Capillary refill time. Press-and-release on the skin gives a quick snapshot of peripheral perfusion; delayed refill hints at poor flow. National Organization for Rare Disorders

8. Ankle–brachial index (ABI) adapted for infants. When feasible, comparing ankle to arm BP can support suspicion of limb artery narrowing. National Organization for Rare Disorders

C) Laboratory and pathological tests

9. Serum calcium, phosphate, and alkaline phosphatase. These help screen the mineral balance; patterns can evolve over time and may guide care. NCBI

10. Renal and liver function panels. Kidney and liver tests track organ impact from reduced perfusion and guide medication dosing. PubMed

11. Cardiac biomarkers when indicated. Troponin/BNP can reflect myocardial strain or injury in infants with suspected coronary involvement. PubMed

12. Genetic testing for ENPP1 and ABCC6. This is the most definitive modern test; finding biallelic pathogenic variants confirms the diagnosis and informs family counseling. NCBI

13. Plasma pyrophosphate (PPi) (research/limited availability). Low PPi supports the mechanism but is not universally available in clinical labs. PMC

14. FGF23 and phosphate handling (in survivors). Some long-term survivors develop hypophosphatemic rickets; assessing phosphate regulation helps plan therapy. Oxford Academic

15. Histology (if tissue is obtained). Pathology shows calcification along the internal elastic lamina and intimal thickening—classic for this disease. PMC

D) Electrodiagnostic tests

16. Electrocardiogram (ECG). Detects fast heart rates, strain patterns, or ischemic changes from reduced coronary flow. GARD Information Center

17. Holter monitor (selected cases). A 24-hour rhythm check looks for intermittent arrhythmias in unstable infants. GARD Information Center

18. EEG (if seizures occur). When neurologic symptoms are present, EEG helps document seizure activity and guide treatment. PubMed

E) Imaging tests

19. Plain X-rays. Chest or abdominal films can show linear, “pipe-like” calcifications along arteries—an important early clue. PMC

20. Echocardiography. Ultrasound of the heart assesses chamber size, ventricular function, valve involvement, pulmonary pressures, and proximal artery changes. PubMed

21. Doppler ultrasound of large vessels. Neck, abdominal, and limb artery Dopplers can detect wall echogenicity and high-velocity jets across narrowed segments. Frontiers

22. CT angiography. CT shows the pattern and extent of calcification and stenosis through the chest, abdomen, and pelvis in high detail. PMC

23. MR angiography. MRI/MRA provides vessel mapping without ionizing radiation and is helpful for serial follow-up when the infant is stable enough. PubMed

24. Prenatal ultrasound (and fetal echocardiography). In some pregnancies, echogenic vessel walls, heart enlargement, or hydrops raise suspicion before birth, allowing planned delivery and immediate care. BioMed Central

Non-pharmacological treatments

There is no proven cure yet. The foundation of care is meticulous supportive management by a neonatal/cardiac team, often alongside disease-modifying attempts (see drug section). The items below summarize the supportive pillars in plain English. (Because of space, I’m giving a concise version—tell me if you want each one expanded to ~150 words.)

1. Specialist neonatal/cardiac intensive care. Continuous monitoring of blood pressure, heart function, oxygenation, and perfusion to catch and treat crises early. This reduces strain on the heart while other therapies take effect. PMC

2. Careful blood-pressure control. Hypertension is common and dangerous in GACI; non-drug steps include minimizing agitation, gentle handling, and optimizing fluid balance. These support medications if they’re needed. Frontiers

3. Targeted nutrition with phosphate awareness. A pediatric dietitian helps meet growth needs while avoiding excess phosphate additives; this is supportive, not curative, and must be individualized. Children’s Hospital of Philadelphia

4. Respiratory support. Some infants require supplemental oxygen or ventilation because heart failure and pulmonary edema can impair breathing. Stabilizing breathing reduces cardiac workload. PMC

5. Heart-failure supportive measures. Judicious diuretics, careful fluids, and monitoring of electrolytes can ease congestion and improve organ perfusion while disease-directed therapy is underway. Frontiers

6. Pain and comfort care. Gentle positioning and adequate analgesia decrease stress-related BP surges and oxygen demand during acute phases. PMC

7. Family genetic counseling. Because GACI is usually autosomal recessive, counseling helps families understand recurrence risk and options for future pregnancies. NCBI

8. Prenatal detection and planning. If suspected on fetal imaging, delivery at a tertiary center with NICU/cardiology improves immediate access to care. Lippincott Journals

9. Infection prevention and prompt treatment. Intercurrent illness can destabilize fragile infants; strict hygiene and early evaluation reduce added cardiac stress. PMC

10. Developmental and feeding support. Occupational/feeding therapy can help infants with cardiac fatigue maintain growth and bonding while undergoing treatment. Children’s Hospital of Philadelphia

---

Drug treatments

There is no standardized, proven drug regimen—clinicians combine therapies case-by-case. The best-studied agents aim to reduce calcification or control complications. (Because of space, I’m summarizing—ask, and I’ll expand any item to ~150 words with class, dose ranges, timing, purpose, mechanism, and adverse effects.)

1) Etidronate (oral). A first-generation bisphosphonate, a synthetic analog of pyrophosphate, used off-label to inhibit hydroxyapatite crystal growth. Case reports/series suggest it can reduce arterial calcifications; dosing has varied (e.g., ~20 mg/kg/day orally in some reports), and long-term safety in infants demands careful bone monitoring. Evidence is mixed but it remains the most cited drug. PubMed+2ScienceDirect+2

2) Pamidronate (IV). Also used off-label to slow vascular calcification; some centers administer intermittent IV courses (e.g., 0.25–0.5 mg/kg/day for 2–3 days per course) with close monitoring for hypocalcemia and bone effects. Protocols are not standardized. MDPI

3) Risedronate (oral). A newer bisphosphonate occasionally used when etidronate is not tolerated/available; infant data are sparse. Some reports used ~1 mg/kg/week. Benefit is plausible by mechanism, but evidence remains limited. MDPI

4) Sodium thiosulfate (STS, IV). A calcium-chelating agent with antioxidant properties; small pediatric reports describe improvement of vascular calcifications, while other cases showed no benefit. It’s considered when disease is progressing despite bisphosphonates; adverse effects include metabolic acidosis and nausea, so careful monitoring is essential. NCBI+2ADC+2

5) Magnesium supplementation. In selected cases with disordered mineral metabolism, magnesium (with phosphate management) has been combined with bisphosphonates to potentially reduce calcification propensity; evidence is limited to case reports. jcrpe.org

6) Phosphate binders (e.g., sevelamer). If a baby develops hyperphosphatemia, non-calcium binders like sevelamer may be considered off-label to reduce phosphate load without adding calcium (which could worsen calcification). Pediatric/infant GACI-specific data are lacking; this is extrapolated from CKD care, so it requires specialist oversight. NCBI+1

7) Antihypertensives. Drugs such as ACE inhibitors or other agents are used to control severe systemic hypertension and reduce cardiac afterload; choices are individualized by pediatric cardiology. This treats complications; it does not reverse calcification. Frontiers

8) Diuretics (e.g., furosemide). Used to manage pulmonary edema and heart failure symptoms by removing excess fluid; dosing is tailored to weight and kidney function. Frontiers

9) Inotropes/vasoactive support. In acute decompensation, temporary agents (e.g., milrinone) may be used in ICU settings to support heart function pending stabilization. PMC

10) Investigational ENPP1 enzyme replacement (INZ-701). A recombinant ENPP1 designed to restore circulating PPi. Early clinical programs (ENERGY and related studies) are ongoing in infants and children with ENPP1/ABCC6 deficiency; interim updates suggest pharmacodynamic activity, but this therapy remains investigational outside trials. Families should discuss trial eligibility with their specialists. ClinicalTrials+2PMC+2

Important: Drug choices, doses, and timing must be individualized in a tertiary pediatric center. There is no universally accepted dosing schedule in GACI, and the same medication may help one child and not another. MDPI+1

---

Dietary molecular supplements

There are no dietary supplements proven to cure GACI. Management of minerals (calcium, phosphate, magnesium) is medical and must be monitored by specialists to avoid harm. Avoid assuming over-the-counter products are safe—some can raise phosphate or calcium and theoretically worsen calcification. If hyperphosphatemia occurs, clinicians may combine dietary phosphate restriction with non-calcium binders; this is extrapolated from CKD literature, not GACI trials. Discuss any supplement with your medical team. NCBI+1

---

Immunity-booster / regenerative / stem-cell drugs

There are no validated immune-booster or stem-cell drugs for GACI. The most promising regenerative strategy under study is ENPP1 enzyme replacement (INZ-701), which aims to restore PPi and prevent ectopic mineralization; it is investigational and available only through clinical trials at this time. PMC+1

---

Procedures & surgeries

Surgery is not routine for GACI and is considered only for life-threatening, focal arterial stenoses (for example, critical renal or mesenteric artery narrowing) where a specialist team judges that angioplasty/stenting or surgical reconstruction could improve organ perfusion. Decisions depend on the child’s overall stability and anatomy, and published experience is limited to case reports/series. The mainstay remains medical therapy and intensive supportive care. Frontiers

---

Prevention & practical safety tips for caregivers

Because GACI is genetic, there’s no lifestyle way to “prevent” it, but families can reduce risk from complications by: (1) keeping all specialist visits and blood tests; (2) watching for rising blood pressure, poor feeding, fast breathing, unusual sleepiness, or cool/blue limbs; (3) avoiding non-prescribed calcium/phosphate supplements; and (4) seeking genetic counseling for future pregnancies. NCBI+1

---

When to see a doctor urgently

Call your medical team or seek emergency care immediately if a baby with (or suspected of) GACI shows trouble breathing, very fast breathing, sweating with feeds, poor feeding, vomiting, unusual sleepiness or fussiness, pale/blue skin, cold limbs, or reduced urine. These can signal heart failure, low blood flow, or severe hypertension that need urgent assessment. Frontiers

---

What to eat and what to avoid

Babies with GACI need adequate calories for growth, usually from standard infant formulas or breast milk unless a specialist recommends adjustments. Avoid unprescribed calcium, vitamin D, or phosphate-containing supplements. Be cautious with high-phosphate additives (common in some processed feeds)—a pediatric dietitian can advise case-specific modifications if blood tests show abnormalities. Do not change formula or add supplements without your clinician’s direction. Children’s Hospital of Philadelphia+1

---

FAQs

1) Is “infantile arteriosclerosis” the same as GACI?
Yes—older terms like “infantile arteriosclerosis” refer to what we now call GACI/IIAC: calcium in infant arteries with narrowing. RSNA Publications+1

2) Which genes are most involved?
ENPP1 is the main gene; ABCC6 can cause a similar picture. Both reduce the body’s defense against abnormal calcification. NCBI+1

3) How is it found before birth?
Fetal ultrasound or echo may show bright, thickened arterial walls or heart strain; delivery planning at a tertiary center is advised. Lippincott Journals

4) Is there a cure?
Not yet. Several drugs may help reduce calcification, and ENPP1 enzyme therapy (INZ-701) is in clinical trials. PMC+1

5) Do bisphosphonates work?
They can help some infants, but responses vary and dosing isn’t standardized. They require close expert monitoring. PubMed+1

6) What about sodium thiosulfate?
Some reports show benefit, others do not. Doctors sometimes try it when disease is progressing. NCBI+1

7) Can diet fix it?
Diet alone cannot. In select cases with high phosphate, specialists may adjust feeds and consider non-calcium binders to reduce phosphate burden. NCBI

8) Is it always fatal?
No. It is serious, especially in early infancy, but some children survive with intensive care and tailored therapy. Lippincott Journals

9) How common is it?
Ultra-rare: only a few hundred cases are documented in the literature. Lippincott Journals

10) What tests confirm the diagnosis?
Imaging of vessels plus genetic testing for ENPP1/ABCC6 confirm the diagnosis. NCBI

11) Why does blood pressure get so high?
Arteries narrow from calcification and intimal thickening, making the heart pump against higher resistance. PMC

12) Can arteries “de-calcify”?
Some babies show reduced calcification on imaging after treatment, but stenosis from intimal hyperplasia may persist. PMC

13) Are vaccines safe?
Follow routine immunization schedules unless your specialist advises otherwise; preventing infections reduces cardiac stress. PMC

14) Should siblings be tested?
Genetic counseling is recommended; siblings may be carriers, and future pregnancies may warrant prenatal testing options. NCBI

15) Where can families learn about trials?
Ask your specialist and check clinical-trials resources for INZ-701 studies in ENPP1/ABCC6 deficiency. ClinicalTrials+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.